Companies › Great Novel Therapeutics Biotech & Medicals
1 active drug program in 20 registered trials: 12 Phase 2, 6 Phase 1, 2 Phase 3; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Chidamide Histone deacetylase (HDAC) inhibitor | HDAC (class I/II) | Phase 2 | Relapsed or Refractory Peripheral T-cell Lymphoma; Metastatic Microsatellite-stable Colorectal Cancer; Diffuse Large B-Cell Lymphoma (DLBCL); Colorectal Cancer Metastatic … | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06685276 | Chidamide | Phase 2 | Colorectal Cancer Metastatic | Oncology | Dec 2026 |
| NCT05958719 | Chidamide | Phase 2 | Peripheral T Cell Lymphoma | Oncology | Dec 2026 |
| NCT06451861 | Chidamide | Phase 2 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT06764017 | Chidamide | Phase 2 | Diffuse Large B-Cell Lymphoma | Oncology | Dec 2026 |
| NCT07304232 | Chidamide | Phase 2 | Allogeneic Hematopoietic Cell Transplantation (HCT) | Oncology | Dec 2026 |
| NCT05682755 | Chidamide | Phase 1 | Leukemia, Myeloid, Acute | Oncology | Dec 2026 |
| NCT05768503 | Chidamide | Phase 3 | Metastatic Microsatellite-stable Colorectal Cancer | Oncology | Jan 2027 |
| NCT05833724 | Chidamide | Phase 2 | Relapsed or Refractory Peripheral T-cell Lymphoma | Oncology | Jun 2027 |
| NCT07545967 | Chidamide | Phase 1 | Head and Neck Squamous Cell Carcinoma HNSCC | Oncology | Jul 2027 |
| NCT07093710 | Chidamide | Phase 1 | Peripheral T Cell Lymphoma | Oncology | Aug 2027 |
| NCT03031262 | Chidamide | Phase 1 | AML | Oncology | Dec 2027 |
| NCT07538180 | Chidamide | Phase 2 | Newly Diagnosed MYC/BCL2 Double-expressor DLBCL | Oncology | Dec 2027 |
| NCT05270200 | Chidamide | Phase 1 | Leukemia, Myeloid, Acute | Oncology | Dec 2027 |
| NCT07518602 | Chidamide | Phase 2 | Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) | Oncology | Mar 2028 |
| NCT07058103 | Chidamide | Phase 2 | Angioimmunoblastic T-Cell Lymphoma Recurrent | Oncology | Apr 2028 |
| NCT07168317 | Chidamide | Phase 2 | New Diagnosed Angioimmunoblastic T-Cell Lymphoma | Oncology | Aug 2028 |
| NCT07754890 | Chidamide | Phase 1 | Cutaneous T-cell Lymphoma (CTCL) | Oncology | Dec 2028 |
| NCT07507318 | Chidamide | Phase 2 | Diffuse Large B-Cell Lymphoma | Oncology | Jun 2029 |
| NCT07493109 | Chidamide | Phase 3 | Diffuse Large B-Cell Lymphoma (DLBCL) | Oncology | Sep 2029 |
| NCT07493148 | Chidamide | Phase 2 | Diffuse Large B-Cell Lymphoma (DLBCL) | Oncology | Dec 2029 |
Italfarmaco Acrotech Biopharma Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.